**VERIDOC AI**

AI-Powered Source Data Verification Platform

**Project Initiation Document**

*Version 1.0 \| Confidential*

| **Document Status** | Draft        |
|---------------------|--------------|
| **Version**         | 1.0          |
| **Classification**  | Confidential |
| **Date**            | 10 June 2026 |

# EXECUTIVE SUMMARY

VeriDoc AI is a next-generation, AI-powered Source Data Verification
(SDV) platform designed to transform the clinical trial monitoring
process. The platform addresses one of the most resource-intensive
activities in clinical research — the manual verification of source
medical documentation against electronic Case Report Form (eCRF) data —
by deploying a fleet of specialized AI agents that automate,
standardize, and accelerate the entire SDV workflow.

Clinical trials across all phases (I–IV) are burdened by increasingly
complex data requirements, global multi-site operations, and rigorous
regulatory demands. Traditional on-site SDV consumes up to 30–35% of
total trial costs and is a primary bottleneck in study timelines.
VeriDoc AI directly addresses this challenge.

## Vision Statement

<table>
<colgroup>
<col style="width: 100%" />
</colgroup>
<thead>
<tr>
<th><p>To become the global standard for AI-assisted Source Data
Verification in clinical trials,</p>
<p>enabling faster, more accurate, and fully auditable verification
across any therapeutic area,</p>
<p>any phase, and any geography — while maintaining full compliance with
GCP, ALCOA+,</p>
<p>21 CFR Part 11, EMA Annex 11, and ICH E6(R3).</p></th>
</tr>
</thead>
<tbody>
</tbody>
</table>

## Core Problem Being Solved

| **Challenge** | **Current Impact** |
|----|----|
| Manual SDV is slow and expensive | 30–35% of trial costs; major timeline delays |
| Human error in data comparison | Missed discrepancies; regulatory findings |
| Global heterogeneity of EMR systems | No unified data pipeline; manual workarounds |
| ALCOA+ compliance verification | Inconsistent; relies on individual CRA judgment |
| AE/SAE timeline monitoring | Delays in regulatory reporting; risk of non-compliance |
| Cross-domain data consistency | Rarely performed systematically; high oversight |
| Query management | Manual generation; slow resolution cycles |

## Proposed Solution

VeriDoc AI integrates directly with Electronic Medical Records (EMR)
systems via HL7 FHIR and proprietary adapters, and with Medidata Rave
(primary eCRF) via its API. A multi-agent AI architecture performs
parallel, continuous verification across all data domains, generating
structured queries, clinical significance assessments, and
regulatory-compliant reports — all with a complete audit trail.

## Key Value Propositions

- 70–85% reduction in manual SDV effort for routine data fields

- Real-time ALCOA+ compliance verification across all source documents

- Automated clinical significance assessment for laboratory and
  instrumental findings

- Proactive AE/SAE timeline monitoring with regulatory deadline tracking

- Cross-domain consistency checks (Medical History, AE, Labs, ConMed)

- Risk-based site prioritization aligned with ICH E6(R3) principles

- Full audit trail compliant with 21 CFR Part 11 and EMA Annex 11

- Global scalability across any number of sites, studies, and
  geographies

## Business Model

| **Tier** | **Target Client** | **Pricing Model** |
|----|----|----|
| Core | Academic centers, small CROs, investigator-led trials | Per-patient, per-month fee (~\$15–25) |
| Standard | Mid-size CROs and Sponsors, 1–5 concurrent studies | SaaS subscription (~\$3,000–8,000/month per study) |
| Enterprise | Top-20 CROs, Big Pharma, multiple concurrent studies | Annual enterprise license (\$200,000–2,000,000/year) |

## Financial Summary

| **Metric** | **Value** | **Notes** |
|----|----|----|
| Phase 1 MVP Investment | ~\$800K – \$1.2M | Development, integration, validation |
| Target Break-even | Month 20–24 | Based on 10+ paying clients |
| Year 1 ARR Target | \$200K – \$400K | 2–3 pilot clients |
| Year 2 ARR Target | \$1.5M – \$3M | 10–15 clients |
| Year 3 ARR Target | \$5M – \$12M | 30–50 clients |

## Critical Success Factors

1.  Regulatory Affairs strategy established before development begins
    (21 CFR Part 11, Annex 11, ICH E6(R3))

2.  At least one CRO or Sponsor pilot partner engaged during design
    phase

3.  Official Medidata Technology Partner status obtained for full API
    access

4.  System validation (IQ/OQ/PQ) completed before commercial deployment

5.  Human-in-the-loop architecture maintained for all clinical decisions

# 1. PROJECT OVERVIEW

## 1.1 Background and Context

Source Data Verification (SDV) is a fundamental component of Good
Clinical Practice (GCP) and is required by all major regulatory
authorities including the FDA (21 CFR Part 312), EMA (Directive
2001/20/EC), and ICH E6(R3). SDV ensures that data entered into the
electronic Case Report Form (eCRF) accurately reflect the original
source documentation — medical records, laboratory reports, imaging
results, patient diaries, and other source materials.

In traditional clinical trial operations, SDV is performed manually by
Clinical Research Associates (CRAs) during on-site monitoring visits.
This process is labor-intensive, time-consuming, and prone to human
error, particularly as trials grow in complexity, patient numbers, and
geographic distribution. For a Phase III trial with 150 sites and 3,000
patients, manual SDV can require thousands of CRA hours per year.

The introduction of risk-based monitoring (RBM) under ICH E6(R3) has
shifted emphasis toward centralized statistical monitoring and targeted
SDV, creating an opportunity for AI-powered tools to perform continuous,
comprehensive centralized monitoring that was previously impractical at
scale.

## 1.2 Project Scope

<table>
<colgroup>
<col style="width: 100%" />
</colgroup>
<thead>
<tr>
<th><strong>IN SCOPE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><p>• AI-powered SDV: automated comparison of EMR source data vs.
eCRF data (Medidata Rave)</p>
<p>• ALCOA+ compliance verification for all source documentation</p>
<p>• Laboratory data clinical significance assessment</p>
<p>• AE/SAE and Concomitant Medication SDV and timeline monitoring</p>
<p>• Cross-domain consistency checks (Medical History, AE/SAE, Labs,
ConMed, Vitals)</p>
<p>• Medical review of eCRF-entered data</p>
<p>• Automated query generation and lifecycle management in Medidata
Rave</p>
<p>• Risk-based site scoring and monitoring prioritization</p>
<p>• eTMF integration (Veeva Vault TMF, Montrium, Wingspan)</p>
<p>• Multi-site, multi-study, global deployment capability</p>
<p>• Regulatory-compliant audit trail (21 CFR Part 11 / EMA Annex
11)</p>
<p>• Multi-language support for documentation and queries</p></td>
</tr>
</tbody>
</table>

<table>
<colgroup>
<col style="width: 100%" />
</colgroup>
<thead>
<tr>
<th><strong>OUT OF SCOPE (Phase 1)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><p>• Electronic data capture (eCRF) — integration only, not
replacement</p>
<p>• CTMS (Clinical Trial Management System) functionality</p>
<p>• Pharmacovigilance database submission (MedWatch,
EudraVigilance)</p>
<p>• Direct patient-facing interfaces</p>
<p>• Statistical analysis plan execution</p>
<p>• Biostatistics or data management functions</p></td>
</tr>
</tbody>
</table>

## 1.3 Target Users

| **User Role** | **Organization** | **Primary Use** | **Access Level** |
|----|----|----|----|
| CRA / Monitor | CRO / Sponsor | Perform and review SDV | Full SDV workflow |
| Data Manager | CRO / Sponsor | Query management, data review | Query + data review |
| Medical Monitor | CRO / Sponsor | Medical review, AE/SAE review | Medical review module |
| Site Coordinator | Clinical Site | Respond to queries | Query responses only |
| Principal Investigator | Clinical Site | Review and confirm clinical findings | Medical sign-off |
| Sponsor Representative | Pharma / Biotech | Study oversight, risk review | Read-only dashboard |
| Regulatory Affairs | CRO / Sponsor | Compliance and audit reports | Reports and audit trail |
| System Administrator | Any | User management, configuration | Full admin access |

# 2. FUNCTIONAL REQUIREMENTS

## 2.1 Source Data Verification Engine

The core SDV engine performs field-level comparison between data
extracted from EMR source documents and data entered in Medidata Rave
eCRF. The engine must handle:

- Exact value matching for numerical data (lab values, vital signs,
  dates)

- Semantic matching for clinical terminology using SNOMED CT and MedDRA
  mappings

- Unit conversion and normalization (e.g., mg/dL to mmol/L, Fahrenheit
  to Celsius)

- Date format normalization across regional conventions

- Multi-language text comparison for international sites

- Handling of missing, partial, or illegible source data with
  appropriate flagging

## 2.2 ALCOA+ Compliance Verification

Every source document ingested by the system must be assessed against
the ALCOA+ framework as defined by FDA and ICH guidelines:

| **ALCOA+ Principle** | **Verification Method** | **Output on Failure** |
|----|----|----|
| Attributable | Detect presence of author signature, credentials, date/time of documentation | Query: missing attribution |
| Legible | OCR confidence scoring; handwriting detection; image quality assessment | Flag for human review if score \<95% |
| Contemporaneous | Compare document timestamp against event date; configurable time windows | Query: delayed documentation with required explanation |
| Original | Document fingerprinting; hash verification; version control tracking | Flag: potential copy without certification |
| Accurate | Detect corrections without initials/date/reason; physiological plausibility checks | Query: non-compliant correction identified |
| Complete | Protocol-driven checklist per visit; mandatory field verification | Query: missing required documentation |
| Consistent | Cross-document consistency across visits and data domains | Query: inconsistency identified between documents |
| Enduring | File format and storage medium validation | Alert: non-durable format detected |
| Available | Accessibility check at time of audit simulation | Alert: document not retrievable |

## 2.3 Laboratory Data Management

The laboratory module performs multi-level verification and assessment:

- Extraction and normalization of lab results from EMR using LOINC
  coding

- Verification of lab values, units, collection dates, and methods
  against eCRF entries

- Reference range comparison using site-specific certified laboratory
  normals

- Grade classification per CTCAE v5.0 for oncology trials or NCI
  criteria

- Clinical significance assessment with three-tier alert system (Low /
  Moderate / Critical)

- Trend analysis across visits with progressive worsening detection

- Protocol-specific threshold monitoring (e.g., neutrophil counts, liver
  enzymes)

- Automatic cross-reference: clinically significant lab findings vs.
  AE/SAE reporting

## 2.4 Adverse Event and SAE Verification

The AE/SAE module provides comprehensive monitoring of safety data:

- Verification that all AEs documented in source are recorded in eCRF

- CTCAE Grade verification against source documentation narrative

- Start date, end date, and outcome consistency checks

- Causality assessment verification: related/not related supported by
  documentation

- SAE regulatory timeline monitoring: 7-day (fatal/life-threatening) and
  15-day (other) reporting windows for FDA and EMA

- SAE cross-verification: hospitalization records, concomitant
  medications, laboratory data

- Protocol Deviation flagging for unreported or late-reported SAEs

## 2.5 Concomitant Medication Verification

- Verification of all ConMed entries against medical records and
  prescription documentation

- Start/stop date consistency with medical history and AE documentation

- ATC/WHO Drug Dictionary coding verification

- Prohibited medication check against protocol exclusion criteria

- Drug-drug interaction screening with investigational product

- Indication cross-reference with Medical History and AE data

## 2.6 Cross-Domain Consistency Checks

The Consistency Agent performs matrix-based cross-verification across
all data domains:

| **Domain Pair** | **Example Check** |
|----|----|
| Medical History ↔ AE/SAE | Pre-existing condition worsening documented as AE; baseline vs. new onset determination |
| Medical History ↔ ConMed | Documented diagnosis should have corresponding medication or documented reason for absence |
| Medical History ↔ Labs | Diagnoses such as diabetes should correspond to relevant laboratory assessments |
| AE/SAE ↔ Labs | AE of nephrotoxicity should be supported by creatinine elevation; grade should match severity |
| AE/SAE ↔ ConMed | Adverse event treatment should be documented as concomitant medication |
| AE/SAE ↔ Vitals | AE of hypotension should correspond to documented blood pressure values |
| Labs ↔ ConMed | Dose modifications for toxicity should trigger review of subsequent lab values |
| Informed Consent ↔ All Procedures | Date of informed consent must precede all study procedures |

## 2.7 Query Management

The Query Agent automates the full query lifecycle within Medidata Rave:

- Automated query generation with structured, protocol-specific language

- Priority classification: Critical / High / Medium / Low

- Direct integration with Medidata Rave Discrepancy Note system via API

- Query routing to appropriate site personnel based on query type

- Response evaluation: system assesses whether response resolves the
  query

- Automated follow-up for unresolved or unsatisfactory responses

- Escalation workflow for queries unanswered beyond configurable
  thresholds

- Query metrics and KPI tracking by site, investigator, and data domain

# 3. TECHNICAL ARCHITECTURE

## 3.1 System Architecture Overview

VeriDoc AI is built on a cloud-native, microservices architecture
deployed across regional cloud instances to meet data residency
requirements. The system is organized into four primary layers:

| **Layer** | **Components** | **Technology Stack** |
|----|----|----|
| Presentation Layer | Sponsor Portal, CRO Portal, Site Portal, Mobile App, REST API | React.js, TypeScript, REST/GraphQL |
| Integration Layer | EMR Adapters, eCRF Connector, eTMF Connector, Identity Provider | FHIR R4, HL7 v2, OAuth 2.0, SAML 2.0 |
| AI Processing Layer | Orchestrator Agent, 10 Specialized Agents, LLM Engine, OCR Engine | LangGraph, Python, Claude/GPT-4, Azure AI |
| Data Layer | Patient Data Store, Audit Database, Document Store, Configuration DB | PostgreSQL, MongoDB, Azure Blob, Redis |
| Infrastructure Layer | Regional cloud clusters, CDN, WAF, HSM, Monitoring | AWS / Azure, Terraform, Kubernetes |

## 3.2 AI Agent Architecture

The platform deploys 10 specialized AI agents coordinated by an
Orchestrator Agent. Each agent is purpose-built for a specific SDV
domain and operates as an autonomous, stateful unit with defined tools,
decision logic, and escalation pathways.

| **Agent** | **Primary Function** | **Key Tools** | **Human Escalation Trigger** |
|----|----|----|----|
| Orchestrator | Task planning, agent coordination, priority management | All agent APIs, Rave API, Protocol DB | Conflicting findings across agents |
| SDV Agent | Field-level source vs. eCRF comparison | EMR connector, Rave API, NLP engine | Semantic ambiguity, critical mismatch |
| ALCOA+ Agent | Regulatory compliance of source documents | OCR engine, timestamp analyzer, hash verifier | Legibility score \<85%, potential fraud indicators |
| Lab Agent | Lab extraction, verification, clinical significance | LOINC DB, CTCAE classifier, trend analyzer | Critical values, Grade 3+ findings |
| AE/SAE Agent | Safety data verification, timeline monitoring | MedDRA encoder, timeline calculator, Rave API | All SAE findings, causality disputes |
| ConMed Agent | Medication verification and interaction screening | WHO Drug Dictionary, interaction DB, ATC coder | Prohibited medications, serious interactions |
| Consistency Agent | Cross-domain data consistency matrix | All domain data, protocol rules engine | Clinically significant inconsistencies |
| Query Agent | Query generation, lifecycle management | Rave Query API, template library, NLP writer | Complex clinical disputes, PI escalations |
| Risk Agent | Site risk scoring, monitoring prioritization | Analytics engine, historical data, risk model | Risk score \>7/10, sudden risk changes |
| Report Agent | SDV reports, visit letters, eTMF filing | Document generator, eTMF API, template engine | Regulatory submission reports |

## 3.3 EMR Integration Framework

The Universal EMR Connector Framework provides adapters for all major
EMR systems and a fallback pathway for non-standard systems. All data is
normalized to the FHIR R4 Unified Patient Data Model before processing.

| **Integration Type** | **Target Systems** | **FHIR Resources Used** |
|----|----|----|
| Native FHIR R4 | Epic, Cerner, Oracle Health, NHS SPINE | Patient, Encounter, Observation, Condition, MedicationRequest, AdverseEvent, DiagnosticReport, DocumentReference, Procedure |
| HL7 v2.x Adapter | Older hospital systems, Siemens, Agfa | Mapped to FHIR via HL7 v2 translation layer |
| Proprietary API | Country-specific EMR systems | Custom adapter with FHIR normalization |
| Semi-manual Import | Systems without API access | Structured PDF/Excel import with AI extraction |
| Document OCR | Paper records, scanned documents | OCR + NLP extraction to FHIR DocumentReference |

## 3.4 Medidata Rave Integration

Medidata Rave is the primary eCRF integration target. The platform uses
the Medidata Rave Web Services (MDRWS) API for bidirectional data
exchange:

- READ operations: Subject data, CRF field values with audit trail,
  query status, protocol deviations, randomization data, freeze/lock
  status

- WRITE operations: Open discrepancy notes (queries), update query
  status, set SDV flags per field, flag protocol deviations

- WEBHOOKS: Real-time triggers on new data entry, SAE submission, query
  response

- Requires official Medidata Technology Partner agreement for production
  API access

## 3.5 Security and Compliance Architecture

| **Requirement** | **Implementation** |
|----|----|
| 21 CFR Part 11 | Electronic signatures with biometric confirmation; complete, time-stamped audit trail; system access controls; validated system status |
| EMA Annex 11 | Change control procedures; data integrity controls; backup and recovery; audit trail review capability |
| GDPR Article 9 | Pseudonymization of all patient-identifiable data at ingestion; data residency enforcement; consent management; right to erasure workflow |
| HIPAA / HITECH | PHI encryption at rest (AES-256) and in transit (TLS 1.3); access controls; breach notification procedures |
| ISO 27001 | Information security management system; risk assessment; security incident management |
| Data Residency | Regional cloud instances: Americas (AWS us-east), EMEA (Azure West Europe), APAC (AWS ap-southeast); China isolated instance |
| Encryption | AES-256 at rest; TLS 1.3 in transit; HSM for key management; field-level encryption for PII |
| Access Control | Role-based access control (RBAC); multi-factor authentication; session management; IP allowlisting for site access |

# 4. REGULATORY AND COMPLIANCE STRATEGY

## 4.1 Applicable Regulations and Guidelines

VeriDoc AI must comply with the following regulatory frameworks as a
system used in GCP-regulated clinical trials:

- ICH E6(R3) Good Clinical Practice — primary GCP guideline; emphasizes
  risk-based and technology-enabled approaches

- ICH E8(R1) General Considerations for Clinical Studies — quality by
  design principles

- FDA 21 CFR Part 11 — Electronic Records and Electronic Signatures

- FDA 21 CFR Part 312 — Investigational New Drug Applications

- EMA Annex 11 — Computerised Systems in GxP environments

- EU Regulation 536/2014 — Clinical Trials Regulation

- PMDA ERES Guidelines (Japan)

- NMPA Clinical Trial Data Management Guidelines (China)

- ANVISA RDC 204/2017 (Brazil)

## 4.2 Computer System Validation (CSV) Strategy

As a system used in GCP-regulated activities, VeriDoc AI requires formal
Computer System Validation (CSV) before use in any clinical trial. The
validation lifecycle follows the GAMP 5 framework:

| **Validation Phase** | **Activities** |
|----|----|
| User Requirements Specification (URS) | Documented functional and non-functional requirements traceable to regulatory standards |
| Functional Specification (FS) | Detailed specification of system functions and behaviors |
| Design Qualification (DQ) | Verification that the system design meets specified requirements |
| Installation Qualification (IQ) | Verification that the system is installed correctly in the target environment |
| Operational Qualification (OQ) | Verification that the system operates as specified throughout operational ranges |
| Performance Qualification (PQ) | Verification that the system performs consistently in the intended use environment |
| Ongoing Validation | Change control procedures; periodic review; revalidation upon significant changes |

## 4.3 Audit Trail Requirements

All system actions must be captured in a complete, secure, and
unalterable audit trail including:

- User identity, role, and access timestamp for every system interaction

- All data accessed, modified, or deleted with before/after values

- All queries generated, modified, and closed with rationale

- All AI agent decisions with supporting evidence and confidence scores

- All system configuration changes

- All login attempts (successful and failed)

Audit trail data must be retained for a minimum of 15 years post-study
completion, or as required by the longest applicable regulatory
retention period.

## 4.4 Human-in-the-Loop Requirements

VeriDoc AI operates as a decision-support tool. The following clinical
decisions require qualified human review and approval before any action
is taken:

| **Decision Type** | **Required Reviewer** |
|----|----|
| SAE causality assessment | Medical Monitor (physician) |
| Protocol Deviation determination | CRA + Medical Monitor |
| Clinical significance of laboratory findings | Medical Monitor |
| Query closure for complex clinical disputes | Senior CRA / Medical Monitor |
| Site escalation recommendations | Clinical Operations Lead |
| Regulatory reporting decisions | Regulatory Affairs + Medical Monitor |
| Study halt or suspension recommendations | Sponsor Medical Officer |

# 5. IMPLEMENTATION ROADMAP

## 5.1 Phased Delivery Approach

The project is structured in four phases over 36 months, with each phase
delivering incremental value and progressively expanding capability and
geographic reach.

### Phase 1 — Foundation and MVP (Months 1–12)

<table>
<colgroup>
<col style="width: 100%" />
</colgroup>
<thead>
<tr>
<th><strong>Phase 1 Objectives</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><p>Deliver a production-ready MVP with core SDV capabilities for
EU/US markets.</p>
<p>Onboard 2–3 pilot CRO or Sponsor clients for real-world
validation.</p>
<p>Achieve Medidata Technology Partner status.</p>
<p>Complete initial regulatory documentation and begin IQ/OQ
validation.</p></td>
</tr>
</tbody>
</table>

| **Sprint / Milestone** | **Deliverables** |
|----|----|
| Sprints 1–3 (M1–M3) | Platform architecture; FHIR R4 integration framework; Medidata Rave API integration; core SDV Agent |
| Sprints 4–5 (M4–M5) | ALCOA+ Agent; Lab Agent with clinical significance engine; LOINC/MedDRA/SNOMED integration |
| Sprints 6–7 (M6–M7) | AE/SAE Agent with timeline monitoring; ConMed Agent with drug interaction screening |
| Sprints 8–9 (M8–M9) | Consistency Agent; Orchestrator Agent; Query Agent with Rave integration |
| Sprints 10–11 (M10–M11) | Risk Agent; Report Agent; CRA and Sponsor portals; audit trail module |
| Sprint 12 (M12) | Pilot client onboarding; IQ/OQ execution; regulatory documentation; performance optimization |

### Phase 2 — Scale and Expand (Months 13–24)

- eTMF integration (Veeva Vault TMF, Montrium, Wingspan)

- Additional eCRF integrations: Veeva Vault EDC, Oracle Inform, REDCap

- Extended EMR adapters for Japan, Brazil, and Middle East systems

- Enterprise tier launch with white-label option

- ISO 27001 certification

- PQ validation completion; FDA and EMA regulatory submissions

- Second regional cluster deployment (Americas or APAC)

### Phase 3 — Global Platform (Months 25–36)

- Full global deployment across all regions including China isolated
  instance

- PMDA (Japan), NMPA (China), ANVISA (Brazil) regulatory submissions

- AI model fine-tuning on accumulated platform data

- Predictive analytics: site performance forecasting, enrollment risk

- Partner ecosystem: CRO white-label program, API marketplace

- Potential strategic partnerships with major eCRF vendors

## 5.2 Resource Requirements

The following core team is required for Phase 1 delivery:

| **Role** | **FTE** | **Key Responsibilities** |
|----|----|----|
| Technical Lead / Architect | 1 | System design, architecture decisions, technical oversight |
| Backend Engineers (Python / AI) | 3 | AI agent development, API integrations, data processing |
| Frontend Engineers | 2 | CRA portal, site portal, sponsor dashboard |
| DevOps / Infrastructure Engineer | 1 | Cloud infrastructure, CI/CD, security, monitoring |
| Medical Informatics Specialist | 1 | FHIR, LOINC, MedDRA, clinical logic validation |
| Regulatory Affairs Consultant | 1 (part-time) | 21 CFR Part 11, Annex 11, CSV strategy, audit readiness |
| Clinical Operations Expert | 1 (part-time) | SDV workflow design, CRA usability, Rave expertise |
| QA / Validation Engineer | 1 | IQ/OQ/PQ execution, test protocols, GAMP 5 compliance |
| Project Manager | 1 | Delivery oversight, client coordination, risk management |

# 6. RISK REGISTER

The following risks have been identified for the project. Each risk is
assessed by probability and impact, with defined mitigation strategies.

| **Risk** | **Probability** | **Impact** | **Mitigation Strategy** |
|----|----|----|----|
| Regulatory non-acceptance of AI-generated SDV findings | Medium | Critical | Maintain human-in-the-loop for all clinical decisions; build full explainability into AI outputs; engage FDA/EMA early via pre-submission meetings |
| Medidata API access restrictions or changes | Low | High | Pursue formal Technology Partner agreement; build abstraction layer to accommodate API versioning; maintain direct eCRF import as fallback |
| EMR integration complexity at global sites | High | Medium | Phased integration approach; semi-manual import fallback; dedicated integration team per region |
| Data residency compliance failures | Low | Critical | Regional cloud deployment from day one; legal review per jurisdiction; GDPR and PIPL compliance by design |
| AI model hallucination in clinical context | Medium | Critical | Confidence thresholds with human review triggers; structured outputs only; extensive medical validation testing; conservative escalation thresholds |
| Computer System Validation delays | Medium | High | Engage CSV consultants early; build validation-ready documentation throughout development; budget 20% contingency |
| Failure to secure pilot clients | Medium | High | Engage clinical network early; offer pilot program with reduced/no cost; academic medical center partnerships |
| Cybersecurity breach of clinical trial data | Low | Critical | ISO 27001 certification; penetration testing; encryption at field level; third-party security audit annually |
| Key personnel attrition | Medium | Medium | Comprehensive documentation; knowledge transfer protocols; competitive compensation; equity participation |

# 7. COMMERCIAL STRATEGY AND GO-TO-MARKET

## 7.1 Market Opportunity

| **Market Metric**                                | **Value**                |
|--------------------------------------------------|--------------------------|
| Global Clinical Trial Management Market (2024)   | ~\$2.8 billion           |
| Clinical Data Management Market CAGR             | ~12.5% (2024–2030)       |
| Estimated SDV cost as % of total trial cost      | 30–35%                   |
| Average Phase III trial monitoring cost          | \$5M – \$15M             |
| Number of active clinical trials globally (2024) | \>400,000                |
| Target addressable market (SDV software)         | ~\$800M – \$1.2B by 2028 |

## 7.2 Competitive Positioning

VeriDoc AI occupies a unique position as a specialized, AI-native SDV
platform — as opposed to the broad clinical trial platforms offered by
Medidata, Veeva, and Oracle, which offer SDV as a minor feature within a
large suite. Key differentiators:

- Only platform built ground-up for AI-driven SDV with ALCOA+ compliance
  at its core

- eCRF-agnostic: integrates with Medidata Rave, Veeva EDC, Oracle
  Inform, and others

- Multi-agent architecture enables parallel, continuous monitoring
  rather than periodic review

- Global EMR integration capability including non-FHIR legacy systems

- Risk-based monitoring alignment with ICH E6(R3) built into the
  platform logic

## 7.3 Go-to-Market Phases

| **Phase** | **Target Segment** | **Strategy** |
|----|----|----|
| Phase 1 (M1–M12) | 2–3 CRO pilot clients | No-cost or heavily discounted pilot in exchange for co-development input, reference status, and case study rights |
| Phase 2 (M13–M24) | 10–15 mid-size CROs and Sponsors | Direct sales; conference presence (DIA, ACRP); Medidata partner marketplace listing |
| Phase 3 (M25–36) | Top-20 CROs; Big Pharma | Enterprise contracts; white-label licensing; channel partner program with regional CROs |

## 7.4 Key Partnerships to Pursue

- Medidata (Dassault Systemes) — Technology Partner Program for Rave API
  access and marketplace visibility

- Veeva Systems — Vault TMF and Vault EDC integration partnerships

- Major CROs (ICON, IQVIA, Syneos, PPD) — pilot program and preferred
  vendor agreements

- Academic Medical Centers — pilot sites with publication and reference
  value

- Regional EMR vendors — pre-built adapter agreements for major markets

# 8. IMMEDIATE NEXT STEPS

The following actions are required to initiate the project formally.
These activities should be completed within 60–90 days of project
approval:

| **Priority** | **Action** |
|----|----|
| \#1 — Critical | Engage a Regulatory Affairs consultant with 21 CFR Part 11 and EMA Annex 11 experience to develop the regulatory strategy and CSV plan before any development begins |
| \#2 — Critical | Identify and approach 2–3 potential pilot CRO or Sponsor clients; negotiate a pilot agreement that includes co-development input and reference rights |
| \#3 — Critical | Apply for Medidata Technology Partner Program to secure full Rave API documentation and support |
| \#4 — High | Finalize technical architecture and select cloud infrastructure provider (AWS or Azure) based on initial target market geography |
| \#5 — High | Recruit core technical team: Technical Lead, 2 Backend Engineers, Medical Informatics Specialist |
| \#6 — High | Develop detailed User Requirements Specification (URS) with input from at least one clinical operations expert |
| \#7 — Medium | Conduct legal review of data privacy requirements for target initial markets (EU/US) |
| \#8 — Medium | Establish company entity and IP protection strategy for the platform |
| \#9 — Medium | Develop detailed financial model and secure initial funding for Phase 1 |
| \#10 — Medium | Define the system name, brand identity, and initial marketing materials for pilot client outreach |

<table>
<colgroup>
<col style="width: 100%" />
</colgroup>
<thead>
<tr>
<th><strong>Decision Gate</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><p>This Project Initiation Document should be reviewed and formally
approved by all key stakeholders</p>
<p>before project commencement. Approval constitutes authorization to
proceed with Phase 1 activities</p>
<p>and commitment of the Phase 1 budget (~$800K – $1.2M).</p>
<p>Approval is requested from: [Sponsor / Project Owner] by: [Target
Approval Date]</p></td>
</tr>
</tbody>
</table>

# APPENDIX A: GLOSSARY

| **Term** | **Definition** |
|----|----|
| ALCOA+ | Attributable, Legible, Contemporaneous, Original, Accurate + Complete, Consistent, Enduring, Available — data integrity principles for source documentation |
| AE | Adverse Event — any untoward medical occurrence in a patient administered an investigational product |
| ATC | Anatomical Therapeutic Chemical classification for medicinal products |
| CRA | Clinical Research Associate — monitor responsible for site oversight and SDV |
| CRF | Case Report Form — document for recording required protocol information on each trial subject |
| CRO | Contract Research Organization — organization providing clinical trial services to sponsors |
| CSV | Computer System Validation — documented process of ensuring a system is suitable for intended use |
| eCRF | Electronic Case Report Form — digital version of the CRF, typically within an EDC system |
| EDC | Electronic Data Capture — computerized system for collection of clinical trial data |
| EMR / EHR | Electronic Medical Records / Electronic Health Records — digital patient medical records |
| eTMF | Electronic Trial Master File — electronic system for storing all essential trial documents |
| FHIR | Fast Healthcare Interoperability Resources — HL7 standard for electronic health data exchange |
| GCP | Good Clinical Practice — international ethical and scientific quality standard for clinical trials |
| ICH | International Council for Harmonisation of Technical Requirements for Pharmaceuticals |
| LOINC | Logical Observation Identifiers Names and Codes — universal standard for laboratory tests |
| MedDRA | Medical Dictionary for Regulatory Activities — medical terminology used in regulatory submissions |
| RBM | Risk-Based Monitoring — approach to clinical trial monitoring that focuses resources on greatest risks |
| SAE | Serious Adverse Event — AE resulting in death, hospitalization, disability, or other serious outcomes |
| SDV | Source Data Verification — process of comparing eCRF data to original source documents |
| SNOMED CT | Systematized Nomenclature of Medicine — comprehensive clinical terminology |
| TMF | Trial Master File — collection of essential documents for a clinical trial |
